Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 15/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050011 | 0.89 | HDAC1 (0.45) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL25253951 | 0.89 | ESR2 (0.47) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL13636373 | 0.88 | ESR2 (0.63) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL14144592 | 0.88 | ESR2 (0.39) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL128335 | 0.87 | HTT (0.44) | ESR2RAB9ASLC18A3 | |
| SCHEMBL19417392 | 0.87 | HTT (0.44) | ESR2RAB9ASLC18A3 | |
| SCHEMBL18466174 | 0.84 | NPC1 (0.42) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL12462974 | 0.84 | ESR2 (0.46) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2884020 | 0.84 | ESR2 (0.57) | ESR2POLBESR1CYP3A4CYP2C9 | |
| SCHEMBL17642590 | 0.83 | KCNH2 (0.41) | ESR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| EP-4436976-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-27 | — | — | US | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097234-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
| US-7820830-B2 | Process for the production of carboxanilides | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1951677-B1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080262242-A1 | Process For the Production of Carboxanilides | SYNGENTA CROP PROTECTION, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1951677-A1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | Syngeta Participations AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057140-A1 | PROCESS FOR THE PRODUCTION OF CARBOXANILIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-05-24 | — | — | WO | disclosed |
| EP-1171113-A1 | COMPOUNDS USEFUL AS PHOSPHOTYROSINE MIMICS | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000062770-A1 | COMPOUNDS USEFUL AS PHOSPHOTYROSINE MIMICS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1045836-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999031066-A1 | PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400579-A1 | SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H2, PMP22 | ESR2 1800/4885POLB 3239/4885ESR1 4815/4885 |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | DDC, AADAT, TYR | ESR2 2494/4885POLB 3686/4885ESR1 3084/4885 |
| US-20080262242-A1 | Process For the Production of Carboxanilides | FGFR2, FGFR4, CCKBR | ESR2 1908/4885POLB 1564/4885ESR1 1688/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | ESR2 2795/4885POLB 43/4885ESR1 3828/4885 |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | DDC, AADAT, TYR | ESR2 2494/4885POLB 3686/4885ESR1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.